{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:47Z","timestamp":1790384327437,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00946-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:04:47Z","timestamp":1784282687000},"page":"2617-2641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in Migraine-Related Outcomes and Functioning at 1 Year: Results of the Longitudinal OVERCOME (US) Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Dawn C.","family":"Buse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Sheikhi","family":"Mehrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Zagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Zakharyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sait","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7929-3704","authenticated-orcid":false,"given":"E. Jolanda","family":"Muenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"4","key":"946_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496\u2013505.","journal-title":"Headache"},{"issue":"5","key":"946_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM, et al. Prevalence and burden of migraine in the United States: a systematic review. Headache. 2024;64(5):516\u201332.","journal-title":"Headache"},{"key":"946_CR3","unstructured":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361."},{"issue":"1","key":"946_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain. 2024;25(1):96.","journal-title":"J Headache Pain"},{"issue":"1","key":"946_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13561-023-00459-2","volume":"13","author":"A Eltrafi","year":"2023","unstructured":"Eltrafi A, Shrestha S, Ahmed A, Mistry H, Paudyal V, Khanal S. Economic burden of chronic migraine in OECD countries: a systematic review. Health Econ Rev. 2023;13(1):43.","journal-title":"Health Econ Rev"},{"issue":"1","key":"946_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-022-01485-x","volume":"23","author":"F Pistoia","year":"2022","unstructured":"Pistoia F, Salfi F, Saporito G, Ornello R, Frattale I, D\u2019Aurizio G, et al. Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities. J Headache Pain. 2022;23(1):110.","journal-title":"J Headache Pain"},{"issue":"1","key":"946_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101.","journal-title":"J Headache Pain"},{"issue":"10","key":"946_CR8","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456\u201370.","journal-title":"Headache"},{"issue":"7","key":"946_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563\u201378.","journal-title":"Cephalalgia"},{"issue":"7","key":"946_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638\u201345.","journal-title":"Headache"},{"issue":"9","key":"946_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, et al. Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408\u201326.","journal-title":"Headache"},{"issue":"6","key":"946_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archinte.1992.00400180125021","volume":"152","author":"RB Lipton","year":"1992","unstructured":"Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992;152(6):1273\u20138.","journal-title":"Arch Intern Med"},{"issue":"1","key":"946_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.1992.03480010072027","volume":"267","author":"WF Stewart","year":"1992","unstructured":"Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64\u20139.","journal-title":"JAMA"},{"issue":"18_supplement","key":"946_CR14","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1212\/WNL.98.18_supplement.2997","volume":"98","author":"R Shapiro","year":"2022","unstructured":"Shapiro R, Nicholson R, Zagar AJ, Kim Y, Reed M, Buse D, et al. Identifying factors pertaining to migraine-related stigma from a novel question set: results of the OVERCOME (US) study (S4. 001). Neurology. 2022;98(18_supplement):2997.","journal-title":"Neurology"},{"issue":"2","key":"946_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62(2):122\u201340.","journal-title":"Headache"},{"key":"946_CR16","doi-asserted-by":"crossref","unstructured":"Ashina S, Muenzel EJ, Nicholson RA, Zagar AJ, Buse DC, Reed ML, et al. Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study. Headache: The Journal of Head and Face Pain. 2024;64(8):1027\u201339.","DOI":"10.1111\/head.14729"},{"key":"946_CR17","doi-asserted-by":"crossref","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study. Headache: The Journal of Head and Face Pain. 2008;48(8):1157\u201368.","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"946_CR18","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"6 Suppl 1","key":"946_CR19","first-page":"S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20\u20138.","journal-title":"Neurology"},{"key":"946_CR20","doi-asserted-by":"crossref","unstructured":"Buse DC, Muenzel EJ, Zagar AJ, Mehrabadi AS, Shapiro RE, Kim G, et al. Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study. Headache: The Journal of Head and Face Pain. 2025;65(4):589\u2013607.","DOI":"10.1111\/head.14925"},{"key":"946_CR21","doi-asserted-by":"crossref","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and Validation of the Migraine-Specific Quality of Life Questionnaire. Headache: The Journal of Head and Face Pain. 1998;38(4):295\u2013302.","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"946_CR22","doi-asserted-by":"crossref","unstructured":"American Headache Society 66th Annual Scientific Meeting June 13\u201316, 2024 San Diego, California. Headache: The Journal of Head and Face Pain. 2024;64(S1):3\u2013232.","DOI":"10.1111\/head.14716"},{"key":"946_CR23","doi-asserted-by":"crossref","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain. 2020;60(10):2340\u201356.","DOI":"10.1111\/head.13966"},{"key":"946_CR24","doi-asserted-by":"crossref","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ, et al. Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache: The Journal of Head and Face Pain. 2021;61(7):992\u20131003.","DOI":"10.1111\/head.14154"},{"issue":"9","key":"946_CR25","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"22","key":"946_CR26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"946_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"24","key":"946_CR28","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"7","key":"946_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"1","key":"946_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-021-01339-y","volume":"22","author":"GF Carvalho","year":"2021","unstructured":"Carvalho GF, Luedtke K, Braun T. Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire. J Headache Pain. 2021;22(1):126.","journal-title":"J Headache Pain"},{"key":"946_CR31","doi-asserted-by":"crossref","unstructured":"Speck RM, Yu R, Ford JH, Ayer DW, Bhandari R, Wyrwich KW. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2021;61(3):511\u201326.","DOI":"10.1111\/head.14031"},{"issue":"1","key":"946_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5.","journal-title":"Nat Rev Dis Primers"},{"key":"946_CR33","doi-asserted-by":"crossref","unstructured":"Andrade C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. J Clin Psychiatry. 2020;81(5).","DOI":"10.4088\/JCP.20f13681"},{"issue":"2","key":"946_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"RB Lipton","year":"2008","unstructured":"Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148\u201358.","journal-title":"Ann Neurol"},{"issue":"5","key":"946_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"946_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41687-023-00552-4","volume":"7","author":"JH Ford","year":"2023","unstructured":"Ford JH, Ye W, Ayer DW, Mi X, Bhandari S, Buse DC, et al. Validation and meaningful within-patient change in Work Productivity and Activity Impairment Questionnaire (WPAI) for episodic or chronic migraine. J Patient Rep Outcomes. 2023;7(1):34.","journal-title":"J Patient Rep Outcomes"},{"key":"946_CR37","doi-asserted-by":"crossref","unstructured":"Seng EK, Buse DC, Klepper JE, S JM, Grinberg AS, Grosberg BM, et al. Psychological Factors Associated With Chronic Migraine and Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache Center. Headache. 2017;57(4):593\u2013604.","DOI":"10.1111\/head.13021"},{"issue":"3","key":"946_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ, et al. Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life: Results of the OVERCOME (US) Study. Neurology. 2024;102(3):e208074.","journal-title":"Neurology"},{"issue":"6","key":"946_CR39","first-page":"613","volume":"50","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Spitzer RL, Williams JB, L\u00f6we B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613\u201321.","journal-title":"Psychosomatics"},{"issue":"1","key":"946_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12874-021-01221-0","volume":"21","author":"FJM M\u00f6lenberg","year":"2021","unstructured":"M\u00f6lenberg FJM, de Vries C, Burdorf A, van Lenthe FJ. A framework for exploring non-response patterns over time in health surveys. BMC Med Res Methodol. 2021;21(1):37.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"946_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02018-z","volume":"23","author":"CA Kolaja","year":"2023","unstructured":"Kolaja CA, Belding JN, Boparai SK, Casta\u00f1eda SF, Geronimo-Hara TR, Powell TM, et al. Survey response over 15 years of follow-up in the Millennium Cohort Study. BMC Med Res Methodol. 2023;23(1):205.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"946_CR42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/head.12878","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280\u20139.","journal-title":"Headache"},{"issue":"1","key":"946_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87352-2","volume":"11","author":"P Irimia","year":"2021","unstructured":"Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Aguirre-Vazquez M, Correa-Fern\u00e1ndez J, Colomina I, et al. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep. 2021;11(1):8286.","journal-title":"Sci Rep"},{"key":"946_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/IJGM.S70456","volume":"8","author":"GPGB Boudreau","year":"2015","unstructured":"Boudreau GPGB, McAllister P, Lipton R, Buse D. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;8:79\u201386.","journal-title":"Int J Gen Med"},{"issue":"4","key":"946_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.mayocp.2019.11.025","volume":"95","author":"S Hutchinson","year":"2020","unstructured":"Hutchinson S, Lipton RB, Ailani J, Reed ML, Fanning KM, Adams AM, et al. Characterization of acute prescription migraine medication use: results from the CaMEO study. Mayo Clin Proc. 2020;95(4):709\u201318.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"946_CR46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, L\u00e1inez MJ, Pascual J, et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009;29(7):751\u20139.","journal-title":"Cephalalgia"},{"issue":"3","key":"946_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ, et al. Migraine-related stigma and its relationship to disability, interictal burden, and quality of life. Neurology. 2024;102(3):e208074.","journal-title":"Neurology"},{"issue":"10","key":"946_CR48","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/head.14401","volume":"62","author":"EK Seng","year":"2022","unstructured":"Seng EK, Shapiro RE, Buse DC, Robbins MS, Lipton RB, Parker A. The unique role of stigma in migraine-related disability and quality of life. Headache. 2022;62(10):1354\u201364.","journal-title":"Headache"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00946-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:18Z","timestamp":1790380998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00946-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00946-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dawn C. Buse has received research support from the United States Food and Drug Administration (FDA) and the National Headache Foundation. She serves as consultant or advisory board member or has received honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Eli Lilly and Company, Ipsen,\u00a0Lundbeck, Novartis, Teva, and Theranica. E. Jolanda Muenzel is an employee and minor stockholder of Eli Lilly and Company. Ali Sheikhi Mehrabadi was an employee and minor stockholder of Eli Lilly and Company at the time of study. He is now an employee of the School of Medicine, University of Limerick, Limerick, Ireland. Anthony J. Zagar was an employee of Eli Lilly and Company and remains a minor stockholder. Armen Zakharyan is employed by TechData, a company contracted by Eli Lilly and Company (sponsor) to perform the statistical analysis. Sait Ashina has received support for consulting, teaching, and honoraria from Allergan\/AbbVie, Amgen, Axsome Therapeutics, Biohaven, Eli Lilly and Company, Impel NeuroPharma, Linpharma, Lundbeck, Novartis, Satsuma, Supernus, Percept, Pfizer, Teva, and Theranica. Robert E. Shapiro serves as consultant or advisory board member or has received honoraria or research support from Eli Lilly and Company, AbbVie, Theranica, Amneal Pharmaceuticals, and Lundbeck. Gilwan Kim is an employee and minor stockholder of Eli Lilly and Company. Robert A. Nicholson is an employee and minor stockholder of Eli Lilly and Company. Richard B. Lipton has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant or advisory board member or has received honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Dr. Reddy's Laboratories (Promius), electroCore, Eli Lilly and Company, GlaxoSmithKline, Eli Lilly and Company, Lundbeck, Merck, Novartis, Pfizer, Teva, Vector, and Vedanta Research. He receives royalties from Wolff's Headache, 8th edition (Oxford University Press, 2009), and Informa. He holds stock\/options in Axon, Biohaven, Cooltech, and Manistee.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Sterling Institutional Review Board (IRB ID #6425\u2013001). All participants provided informed consent to participate in the study. The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, consistent with Good Pharmacoepidemiology Practices and applicable laws.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anthony J Zagar is now retired and Ali Sheikhi Mehrabadi is now an employee of the School of Medicine, University of Limerick, Limerick, Ireland.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}